FDA Publishes Responses to Good Clinical Practice Inquiries

August 22, 2022

FDA Publishes Responses to Good Clinical Practice Inquiries: FDA oversees clinical trials to ensure they are designed, conducted, analyzed and reported according to federal law and FDA’s regulations. The agency’s oversight of clinical trials protects the rights, safety, and welfare of people participating in clinical trials, and supports the development of safe and effective medical products. The agency addresses inquiries related to good clinical practice and human subject protection policies on an ongoing basis. The downloadable spreadsheet below includes inquiries that have been submitted to the FDA as well as the agency’s replies to each inquiry and is searchable by different fields such as topic, date, etc.

Good clinical practice inquiries and responses 2017 - 2021

See the FDA archive  for inquiries for inquiries prior to 2017. Contact gcpquestions@fda.hhs.gov with questions.




FDA NDA

May 18, 2022

FDA Releases Draft Guidance for Industry on Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies

The FDA’s Office of Clinical Pharmacology within the Office of Translational Sciences released a new draft guidance document that, for the first time, clearly addresses the FDA’s recommendations and...

Read the Full Article
Quality & Compliance FDA

April 4, 2023

15 Days of Panic: You Received FDA Form 483 Warning Letter, Now What?

This article has been updated since its original publication date. Remember the last time you were pulled over by the police? Maybe you had a taillight out. Perhaps you were speeding. You may have...

Read the Full Article
Compliance FDA

July 17, 2013

The Importance of Responding to FDA 483 Observations

This article has been updated since its original publication date. The FDA has an established policy that allows companies 15 days to respond in writing to the FDA after issuance of a 483...

Read the Full Article